• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Poland·Healthcare·ADV.WA
Share

Adiuvo Investments S.A. Stocks

PLN 0.61Last Updated 26.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

PLN 2.04M

PLN 0.61
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Adiuvo Investments S.A. operates as a venture capital firm, deploying capital across the entire spectrum of business development, from initial incubation and seed funding to supporting early-stage, startup, and growth-phase companies. Its primary investment focus lies in the medical devices, digital health, and nutraceuticals sectors, specifically targeting opportunities within Poland. The firm typically commits up to €3 million (approximately $3.35 million) per venture, with an intended holding period of three to five years. All investments are made directly from Adiuvo's own balance sheet. Established in 2013, the company maintains its headquarters in Warsaw, Poland.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 09:01

Insiders, a competitor, a philanthropist, and an activist: Who owns shares in Anthropic?

28.10.2026 08:30

Wall Street has identified Broadcom as a major beneficiary of Anthropic's IPO. Who else stands to gain?

28.10.2026 08:01

"Too Big a Chicken": McDonald's Partners Deem the New Menu a Failure

28.10.2026 07:01

Healthcare stocks have become a bet against AI. Should you buy them?

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026